Sanofi

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris Other stock markets 10:58:44 2024-04-19 am EDT			5-day change	1st Jan Change
86.87 ^EUR	+1.92%		+0.47%	-3.21%

04:11pm	Global markets live: P&G, Amex, Blackstone, Apple, Tesla...
03:16pm	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT

SANOFI : JP Morgan reaffirms its Buy rating

April 04, 2022 at 07:38 am EDT

Richard Vosser from JP Morgan retains his positive opinion on the stock with a Buy rating. The target price is unchanged at EUR 105.

Latest news about Sanofi

Global markets live: P&G, Amex, Blackstone, Apple, Tesla...	10:11am
Sector Update: Health Care Stocks Steady Pre-Bell Friday	09:16am	MT
Sector Update: Health Care	08:58am	MT
Sanofi Planning to Restructure US Commercial Operations for Vaccines; Job Losses Likely	05:46am	MT
Sanofi Reportedly Planning to Restructure US Commercial Operations for Vaccines; Job Losses Likely	Apr. 18	MT
Sanofi to overhaul US operations of vaccines, cut jobs	Apr. 18	RE
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Apr. 18	MT
SANOFI : JP Morgan reiterates its Neutral rating	Apr. 18	ZD
Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger	Apr. 18	CI
IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets	Apr. 17	MT
BeiGene to Award Shares Worth $15 Million to 11 Directors	Apr. 17	MT
Sanofi's Frexalimab Reduces Disease Activity in Multiple Sclerosis Patients in Phase 2 Trial	Apr. 17	MT
Sanofi: new positive phase II results in MS	Apr. 17	CF
IDT Australia Signs Master Service Agreement with Sanofi	Apr. 15	MT
Sanofi: progress in hematology trial	Apr. 15	CF
Innate Pharma: progress in hematology trial	Apr. 15	CF
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says	Apr. 12	DJ
European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs	Apr. 12	MT
EU regulator finds no link between weight-loss drugs and suicidal thoughts	Apr. 12	RE
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration	Apr. 09	DJ
Nurix Therapeutics Extends Collaboration With Sanofi, Aims to Nominate Clinical Candidate	Apr. 09	MT
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6	Apr. 09	CI
Sanofi Launches Rabies Vaccine in the UK	Apr. 05	MT
Sanofi: rabies vaccine launched in the UK	Apr. 05	CF
Sanofi Announces Launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK for Pre-exposure and Post-exposure Prophylaxis of Rabies in All Age Groups	Apr. 05	CI

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

CAC 40 , EURO STOXX 50 , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

SANOFI : Looking beyond the quarterly miss, Sanofi remains an attractive bet

February 01, 2024 at 11:26 am EST

Sanofi Sees Trend for Years of Steady Growth: CFO

February 03, 2023 at 03:56 pm EST

More Strategies

Ratings for Sanofi

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

85.23 EUR

Average target price

107.5 EUR

Spread / Average Target

+26.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANOFI	-3.21%	113B
ELI LILLY AND COMPANY	+25.59%	672B
NOVO NORDISK A/S	+23.92%	550B
JOHNSON & JOHNSON	-6.44%	351B
MERCK & CO., INC.	+14.74%	317B
ABBVIE INC.	+7.00%	292B
ASTRAZENECA PLC	+2.96%	211B
NOVARTIS AG	+0.33%	203B
PFIZER, INC.	-11.20%	144B
AMGEN INC.	-7.75%	141B

Other Pharmaceuticals

Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

SANOFI : JP Morgan reaffirms its Buy rating

Latest news about Sanofi

Chart Sanofi

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Sanofi

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals